Skip to main content

07-03-2018 | Oncology | News | Article

News in brief

Dasatinib confirmed as pediatric chronic phase CML option

medwireNews: The tyrosine kinase inhibitor dasatinib is effective and well tolerated as a first- or second-line therapy for children with chronic myeloid leukemia in the chronic phase (CML–CP), research confirms.

“[D]asatinib treatment produced early, deep, and durable responses of clinical importance in this largest prospective trial of pediatric patients with CML-CP to date”, report Lia Gore, from Children’s Hospital Colorado in Aurora, USA, and co-workers.

The phase II trial included 14 patients who had developed resistance to, or were intolerant of, imatinib therapy and 61 patients with a new diagnosis of CML–CP, all of whom were younger than 18 years.

The co-primary endpoint of a major cytogenetic response by over 30% of patients using second-line dasatinib was met within 3 months, while the cumulative rate of a complete cytogenetic response above 55% for first-line dasatinib was met within 6 months.

At 12 months, 41% of patients using second-line dasatinib had achieved a major molecular response and 7% a complete molecular response, rising to 55% and 17%, respectively, by 2 years. The corresponding values for the first-line dasatinib patients were 52% and 8% at 12 months, and 70% and 21% at 2 years.

And after 48 months, 78% of patients using second-line dasatinib and 93% of first-line users were free from progression, the researchers report in the Journal of Clinical Oncology.

A small number of patients (4%) experienced grade 1 or 2 bone growth or developmental adverse events but there were no cases of pleural or pericardial effusion, pulmonary edema, or pulmonary arterial hypertension linked to dasatinib use.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

See also: